We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Adenoviral vectors for gene transfer and therapy
PeriodicalsMedical Sciences

Adenoviral vectors for gene transfer and therapy

Checking your access to this record.

Abstract & Overview

Due to the very efficient nuclear entry mechanism of adenovirus and its low pathogenicity for humans, adenovirus-based vectors have become gene delivery vehicles that are widely used for transduction of different cell types, especially for quiescent, differentiated cells, in basic research, in gene therapy applications, and in vaccine development. As an important basis for their use as gene medicine, adenoviral vectors can be produced in high titers, they can transduce cells in vivo with transgenes of more than 30 kb, and they do not integrate into the host cell genome. Recent advances in the development of adenoviral vectors have brought considerable progress on issues like target cell specificity and tropism modification, long-term expression of the transgene, as well as immunogenicity and toxicity in vivo, and have suggested that the different generations of non-replicative and replicative vectors available today will each suit best for certain applications.

Cite this record

Christoph Volpers, Stefan Kochanek (2004). Adenoviral vectors for gene transfer and therapy. The Journal of Gene Medicine, 6(S1), S164–S171. https://doi.org/10.1002/jgm.496

Copy in another style

Volpers, C., & Kochanek, S. (2004). Adenoviral vectors for gene transfer and therapy. The Journal of Gene Medicine, 6(S1), S164–S171. https://doi.org/10.1002/jgm.496
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.